相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
Megumi Furuta et al.
CANCER SCIENCE (2019)
Bispecific Antibodies in the Treatment of Hematologic Malignancies
Johannes Duell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
Claire Perrinjaquet et al.
CURRENT OPINION IN NEUROLOGY (2019)
Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).
Julie Bailis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop
Bing Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
Dan Liao et al.
FRONTIERS IN PHARMACOLOGY (2019)
An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk
Catherine Diefenbach et al.
BLOOD (2019)
ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
Mark A Rosenthal et al.
NEURO-ONCOLOGY (2019)
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Anthony Stein et al.
DRUG SAFETY (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Investigational CD33-targeted therapeutics for acute myeloid leukemia
Roland B. Walter
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zijun Zhao et al.
ACTA PHARMACEUTICA SINICA B (2018)
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Federica Costa et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall et al.
FRONTIERS IN ONCOLOGY (2018)
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
Anthony S. Stein et al.
BLOOD ADVANCES (2018)
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Tania Jain et al.
BLOOD ADVANCES (2018)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Immunotherapy in hematologic malignancies: past, present, and future
Annie Im et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Checkpoint inhibitors in hematological malignancies
Chi Young Ok et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia
Ibrahim Aldoss et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count
David Sanford et al.
LEUKEMIA & LYMPHOMA (2016)
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Kaichao Feng et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Immune checkpoint blockade in hematologic malignancies
Philippe Armand
BLOOD (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
George S. Laszlo et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Matthew D. Vesely et al.
RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Ugur Sahin et al.
CLINICAL CANCER RESEARCH (2008)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
分享论文
